Ayala Pharmaceuticals Inc (ADXS)

[foggdogg]

Read the recent PR's. And you will see that ADXS is in licensing talks for ADXS11-001. So when approved ADXS has marketing exclusivity for 7 years. Approval AND licensing would be huge for ADXS.

ADXS11-001 is a therapeutic vaccine, like Dendreon’s Provenge, that treats active cancer, but much lower cost because it is not formulated for a specific patient. Unlike currently marketed prophylactic vaccines, ADXS 11-001 treats women who have already developed cervical cancer as a result of human papilloma virus (HPV) infection; the most prevalent sexually transmitted disease in the US today. Advaxis has already filed an IND for a Phase II trial in HPV caused cervical intraepithelial neoplasia (CIN), which is pre-cancerous.